There are some very knowledgable people on this board. Hopefully, one of them will provide a detailed and accurate answer. I believe further trials will need to be done outside of the current one's to market to the sub 16 demogrphic. FDA labeling has not been discussed nor is until you get approval. Yet, Plecanatide has few side effects thus potentially the greater probability to target younget demo. the above is my humble and layman understanding.